Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Pulmonary Arterial Hypertension Pipeline Review, H2 2016 - Therapeutics Report on 39 Companies & 62 Drug Molecules - Research and Markets

Research and Markets
Posted on: 20 Oct 16

Research and Markets has announced the addition of the "Pulmonary Arterial Hypertension - Pipeline Review, H2 2016" report to their offering.

Pulmonary Arterial Hypertension pipeline therapeutics constitutes close to 62 molecules. Out of which approximately 58 molecules are developed by Companies and remaining by the Universities/Institutes.

Our latest report Pulmonary Arterial Hypertension - Pipeline Review, H2 2016 outlays comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Pulmonary Arterial Hypertension Pulmonary arterial hypertension is increased pressure in the pulmonary arteries. These arteries carry blood from heart to lungs to pick up oxygen. Pulmonary arterial hypertension (PAH) is one form of pulmonary hypertension. Symptoms include fatigue, dizziness or fainting spells, chest pressure or pain, swelling (edema) in ankles and legs and shortness of breath (dyspnea). Treatment includes anticoagulant, diuretics and vasodilators. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 8, 11, 31 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Pulmonary Arterial Hypertension Overview
  3. Therapeutics Development
  4. Pipeline Products for Pulmonary Arterial Hypertension - Overview
  5. Pipeline Products for Pulmonary Arterial Hypertension - Comparative Analysis
  6. Pulmonary Arterial Hypertension - Therapeutics under Development by Companies
  7. Pulmonary Arterial Hypertension - Therapeutics under Investigation by Universities/Institutes
  8. Pulmonary Arterial Hypertension Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Pulmonary Arterial Hypertension - Products under Development by Companies
  13. Pulmonary Arterial Hypertension - Products under Investigation by Universities/Institutes
  14. Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development
  • Actelion Ltd
  • APT Therapeutics, Inc.
  • Arena Pharmaceuticals, Inc.
  • Ascendis Pharma A/S
  • AVEO Pharmaceuticals, Inc.
  • Bial - Portela & Ca, S.A.
  • Celsion Corporation
  • Celtaxsys, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Complexa, Inc.
  • Eli Lilly and Company
  • Galectin Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • HitGen LTD
  • Insmed Incorporated
  • INVENT Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Kowa Company, Ltd.
  • Mast Therapeutics, Inc.
  • Mezzion Pharma Co. Ltd.
  • miRagen Therapeutics, Inc.
  • Morphogen-IX Limited
  • Nippon Kayaku Co., Ltd.
  • Nippon Shinyaku Co., Ltd.
  • Novartis AG
  • Peloton Therapeutics, Inc.
  • PhaseBio Pharmaceuticals, Inc.
  • Pluristem Therapeutics Inc.
  • Proteo, Inc.
  • Selten Pharma, Inc
  • Silence Therapeutics Plc
  • SteadyMed Therapeutics, Inc.
  • Suda Ltd
  • Toray Industries, Inc.

For more information about this report visit

View source version on

Business Wire

Last updated on: 20/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.